Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
Daniele Cretella(University of Parma), Roberta Alfieri(University of Parma)
Cited by 67
Related Papers
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
|Journal of Experimental & Clinical Cancer Research|2017|89
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
|Journal of Experimental & Clinical Cancer Research|2019|70
Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
|PLoS ONE|2013|49